JIANGSU, China–(BUSINESS WIRE)–Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout. Currently 36 sites have been identified in 17 states.
The multicenter, randomized, double-blind trial will enroll 580 patients worldwide. For locations of U.S. trial sites and contacts visit clinicaltrials.gov; (NCT05818085). Part 1 of the trial will evaluate the safety and efficacy of ABP-671 at different doses and regimens compared with either placebo or allopurinol, the current standard of care for management of gout in the U.S. Part 2 of the study will compare dosing regimens of ABP-671 selected from Part 1 with placebo in patients not enrolled in Part 1.
Gout is one of the most common types of inflammatory arthritis. It is caused by long-term hyperuricemia, an excessive concentration of serum uric acid (sUA) greater than 7 mg/dL (420 μmol/L). Gout seriously affects people’s quality of life and can increase the probability of sudden cardiac death. Existing drugs for treating chronic gout have poor efficacy and pose serious safety issues, such as leading to kidney failure, sudden cardiac death, or severe liver toxicity.
About Atom Bioscience
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety in animal models of anti-inflammation, and is in a phase 1 clinical trial, For more information, please visit: https://www.atombp.com or atombp.us.
Contacts
For more clinical trial information contact:
https://studykik.com/study-page/gout-16533?utm_source=Opus&utm_medium=Digital
Media Contact:
Daniel Eramian
Opus Biotech Communications
http://opusbiotech.com/
425-306-8716
Business Development Contact:
Roy J. Wu, MBA
Sr. Vice President, Business Development
Atom Bioscience and Pharmaceutical Co., Ltd
Email: roy.wu@atombp.com
NEW YORK, USA - Media OutReach Newswire - 6 September 2024 - Today marks the…
CHENGDE, CHINA - Media OutReach Newswire - 6 September 2024 - With the summer holiday…
HANOI, VIETNAM - Media OutReach Newswire - 6 September 2024 - Hanoi, Vietnam Amidst a…
Tuopai and Shede’s Triumphant Debut in Malaysia: Shede Spirits - Sharing Chinese Wisdom with the…
HONG KONG SAR - Media OutReach Newswire - 6 September 2024 - In celebration of…
MADRID, SPAIN - Media OutReach Newswire - 6 September 2024 - OPPO has announced that…